HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $64 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Rhythm Pharmaceuticals, maintaining a price target of $64. This suggests confidence in the company's future performance.
October 07, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Rhythm Pharmaceuticals, maintaining a price target of $64. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $64 price target by HC Wainwright & Co. indicates a positive outlook for Rhythm Pharmaceuticals. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100